Chi Sheng Pharma & Biotech (4111) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 濟生

Chi Sheng Pharma & Biotech (4111) reported revenue of NT$114.3 million for Oct 2026, +2.2% year on year and -2.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.2 billion (+5.2% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 67 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$102.2 million24/10Nov 2024 NT$108.6 millionDec 2024 NT$120.7 millionJan 2025 NT$107.7 millionFeb 2025 NT$99.1 million25/02Mar 2025 NT$112.7 millionApr 2025 NT$119.6 millionMay 2025 NT$124.5 millionJun 2025 NT$123.6 million25/06Jul 2025 NT$120.3 millionAug 2025 NT$110.6 millionSep 2025 NT$111.3 millionOct 2025 NT$111.8 million25/10Nov 2025 NT$115.5 millionDec 2025 NT$119.7 millionJan 2026 NT$133.3 millionFeb 2026 NT$105 million26/02Mar 2026 NT$118.4 millionApr 2026 NT$127.5 millionMay 2026 NT$124.9 millionJun 2026 NT$122.8 million26/06Jul 2026 NT$118.8 millionAug 2026 NT$118.2 millionSep 2026 NT$117.7 millionOct 2026 NT$114.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$114.3 million+2.2%-2.9%
Sep 2026NT$117.7 million+5.8%-0.4%
Aug 2026NT$118.2 million+6.9%-0.6%
Jul 2026NT$118.8 million-1.2%-3.2%
Jun 2026NT$122.8 million-0.7%-1.6%
May 2026NT$124.9 million+0.3%-2.0%
Apr 2026NT$127.5 million+6.6%+7.6%
Mar 2026NT$118.4 million+5.1%+12.8%
Feb 2026NT$105 million+5.9%-21.2%
Jan 2026NT$133.3 million+23.7%+11.3%
Dec 2025NT$119.7 million-0.9%+3.7%
Nov 2025NT$115.5 million+6.3%+3.2%
Oct 2025NT$111.8 million+9.5%+0.5%
Sep 2025NT$111.3 million+19.0%+0.6%
Aug 2025NT$110.6 million+16.9%-8.1%
Jul 2025NT$120.3 million+25.1%-2.7%
Jun 2025NT$123.6 million+37.9%-0.7%
May 2025NT$124.5 million+23.9%+4.1%
Apr 2025NT$119.6 million+29.5%+6.1%
Mar 2025NT$112.7 million+31.6%+13.7%
Feb 2025NT$99.1 million+23.1%-8.0%
Jan 2025NT$107.7 million+6.7%-10.8%
Dec 2024NT$120.7 million+33.3%+11.2%
Nov 2024NT$108.6 million+20.9%+6.3%
Oct 2024NT$102.2 million+14.1%+9.3%

Jan–Oct 2026 cumulative: NT$1.2 billion (+5.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Chi Sheng Pharma & Biotech vs PEC / Chi Sheng Pharma & Biotech vs Lotus Pharm / Chi Sheng Pharma & Biotech vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16